

Dated: Board of Governors of the Federal Reserve System, August 30, 2012.

**Margaret Shanks,**

*Associate Secretary and Ombudsman.*

[FR Doc. 2012-21808 Filed 9-4-12; 8:45 am]

**BILLING CODE 6210-01-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 28, 2012.

A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) P.O. Box 55882, Boston, Massachusetts 02106-2204:

1. Eastern Bank Corporation, Boston, Massachusetts, to acquire Campello Bancorp, and its subsidiary bank, The Community Bank, A Massachusetts Co-operative Bank, both of Brockton, Massachusetts.

Dated: Board of Governors of the Federal Reserve System, August 30, 2012.

**Margaret Shanks,**

*Associate Secretary and Ombudsman.*

[FR Doc. 2012-21810 Filed 9-4-12; 8:45 am]

**BILLING CODE 6210-01-P**

## GENERAL SERVICES ADMINISTRATION

[Notice—MA—2012—02; Docket No. 2012—0004; Sequence 5]

### Maximum Per Diem Rates for the Continental United States (CONUS)

**AGENCY:** Office of Governmentwide Policy (OGP), General Services Administration (GSA).

**ACTION:** Notice of GSA Per Diem Bulletin FTR 13-01, Fiscal Year (FY) 2013 Continental United States (CONUS) per diem rates.

**SUMMARY:** The General Services Administration's (GSA) Fiscal Year (FY) 2013 per diem review has resulted in lodging and meal allowance changes for certain locations within the continental United States (CONUS) to provide for reimbursement of Federal employees' expenses covered by per diem. All current non-standard area (NSA) lodging per diem rates will remain at FY 2012 levels for FY 2013. The standard lodging per diem rate of \$77 will also continue to remain the same for FY 2013. The meals and incidental expense tiers remain unchanged for FY 2013 and range from \$46-\$71. GSA identified 10 new NSAs: Bakersfield/Ridgecrest, California (Kern County); Stockton, California (San Joaquin County); Hancock and Pearl River Counties in Mississippi; Sidney/Glendive, Montana (Richland and Dawson Counties); Dickinson/Beulah, North Dakota (Stark, Mercer, and Billings Counties); Minot, North Dakota (Ward County); Williston, North Dakota (Williams, Mountrail, and McKenzie Counties); Carlsbad, New Mexico (Eddy County); Watertown, New York (Jefferson County); and Pasco, Washington (Franklin County). The CONUS per diem rates prescribed in Bulletin 13-01 may be found at [www.gsa.gov/perdiem](http://www.gsa.gov/perdiem). GSA bases the lodging rates on the average daily rate that the lodging industry reports to an independent organization. If a lodging rate or a per diem rate is insufficient to meet necessary expenses in any given location, Federal executive agencies can request that GSA review that location. Please review numbers five and six of GSA's per diem Frequently Asked Questions at ([www.gsa.gov/perdiemfaqs](http://www.gsa.gov/perdiemfaqs)) for more information on the special review process.

In addition, the Federal Travel Regulation allows for actual expense reimbursement as provided in §§ 301-11.300 through 301-11.306.

**DATES:** This notice is effective on September 5, 2012 and applies for travel performed on or after October 1, 2012.

**FOR FURTHER INFORMATION CONTACT:** For clarification of content, contact Ms. Jill Denning, Office of Governmentwide Policy, Office of Asset and Transportation Management, at 202-208-7642, or by email at [travelpolicy@gsa.gov](mailto:travelpolicy@gsa.gov). Please cite Notice of GSA Per Diem Bulletin FTR 13-01.

### SUPPLEMENTARY INFORMATION:

#### Background

GSA issues and publishes the CONUS per diem rates, formerly published in Appendix A to 41 CFR Chapter 301, solely on the Internet at [www.gsa.gov/perdiem](http://www.gsa.gov/perdiem). This process, implemented in 2003, ensures more timely changes in per diem rates established by GSA for Federal employees on official travel within CONUS. Notices published periodically in the **Federal Register**, such as this one, now constitute the only notification of revisions in CONUS per diem rates to agencies.

Dated: August 27, 2012.

**Janet Dobbs,**

*Deputy Associate Administrator, Office of Asset and Transportation Management.*

[FR Doc. 2012-21854 Filed 9-4-12; 8:45 am]

**BILLING CODE 6820-14-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

### Enhanced Nanoparticle Cell-Entry for Cancer Therapy

#### *Description of Technology:*

Nanoparticles are being used as a method of drug delivery for the treatment of several diseases, cancer in particular. While the use and versatility of these particles have increased over the years, the speed with which these particles can enter the cells and deliver the drugs remains challenging.

This technology describes a method of modifying nanoparticles to markedly enhance their entry into cancer cells and their delivery of therapeutic drugs. The nanoparticles use a multi-shell calcium phosphate nanocore designed with target-specific siRNA and an endocytosis-enhancing agent. The inventors have shown that the intravenous systemic administration of the enhanced nanoparticles noticeably increases nanoparticle cell-entry along with concomitant delivery of siRNA to cancer cells in vivo. They further demonstrate that the composite calcium phosphate nanoparticle delivery of anti-cancer therapy can preferentially target in vivo tumors and cause tumor growth arrest. Consequently, these modified nanoparticles can exert a greater effect on cancer cells.

#### *Potential Commercial Applications:*

- Nanoparticle delivery of therapeutic treatments to cancers cells.
- Nanoparticle delivery of imaging agents for the identification and monitoring of tumor cells.

#### *Competitive Advantages:*

- Preferentially taken up by cancer cells and not normal cells
- Faster uptake into cells than other nanoparticles
- Tissue and/or cell specific
- Can be customized for targeted therapy

• Extremely versatile—can transport a variety of therapeutic agents and the constructs can incorporate siRNA, chemotherapy agents, targeted drugs, pro-drugs, tracers, and radioactive molecules.

#### *Development Stage:*

- In vitro data available
- In vivo data available (animal)

*Inventors:* King F. Kwong and Lisa A. Tobin (NCI)

*Intellectual Property:* HHS Reference No. E-164-2012/0 — U.S. Patent Application No. 61/648,735 filed 18 May 2012

*Licensing Contact:* Whitney Hastings; 301-451-7337; [hastingsw@mail.nih.gov](mailto:hastingsw@mail.nih.gov)

*Collaborative Research Opportunity:* The Kwong Laboratory, Surgery Branch, NCI, is seeking statements of capability or interest from parties interested in collaborative research to further

develop, evaluate or commercialize nanoparticles in anti-cancer therapy. For collaboration opportunities, please contact King F. Kwong, M.D. at [kwongk2@mail.nih.gov](mailto:kwongk2@mail.nih.gov).

### Therapy for Cancer and Other Diseases Associated With Angiogenesis Driven by Vascular Endothelial Growth Factor-A

*Description of Technology:* Vascular Endothelial Growth Factor-A (VEGF-A) is an angiogenic agent that drives blood vessel formation in solid tumors and other diseases, such as macular degeneration and diabetic retinopathy. Several therapies that target the ability of VEGF to stimulate angiogenesis have been approved. These therapies regulate VEGF-A activity by binding VEGF-A, thereby blocking VEGF-A from binding to its receptor on target cells. This technology utilizes a different approach to regulating VEGF-A activity by providing a VEGF-A protein antagonist that is produced by engineering native VEGF-A protein. The engineered VEGF-A protein disrupts heparan sulfate proteoglycan binding to the VEGF-A/VEGF receptor complex, an activity that is essential for the angiogenic properties of native VEGF-A. The antagonist has a binding affinity for both FLT-1 (VEGFR-1) and KDR/FLK-1 (VEGFR-2) that is equivalent to that of native VEGF-A and specifically antagonizes all VEGF-A-stimulated signaling events.

#### *Potential Commercial Applications:*

Therapy for solid tumors or other diseases associated with angiogenic activity modulated by Vascular Endothelial Growth Factor-A expression.

#### *Competitive Advantages:*

- Specificity/Selectivity
- Cost-effectiveness in production

#### *Development Stage:*

- Early-stage
- In vitro data available
- In vivo data available (animal)

*Inventors:* Donald P. Bottaro and Fabiola Cecchi (NCI)

*Intellectual Property:* HHS Reference No. E-230-2011/0 — U.S. Patent Application No. 61/639,230 filed 27 Apr 2012

*Licensing Contact:* Susan S. Rucker, CLP; 301-435-4478; [ruckersu@mail.nih.gov](mailto:ruckersu@mail.nih.gov)

*Collaborative Research Opportunity:* The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated

cellular responses by competitive displacement of native growth factors and concomitant disruption of heparan sulfate proteoglycan binding to the growth factor-receptor complex. For collaboration opportunities, please contact John Hewes, Ph.D. at [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov).

### Methods for Identifying and Isolating Pancreatic Precursor Cells

*Description of Technology:* Diabetes results when beta cell performance is compromised through loss of cells or reduced cell function. Anti-diabetic drugs that stimulate insulin production, such as sulfonylureas and meglitinides, have limited efficacy when beta cell responsiveness is deficient. There exists a critical need for methods to increase beta cell responsiveness by enhancing cell function or by increasing beta cell numbers.

Notch has been shown to play an important role in pancreas development and diabetes and NIA investigators discovered that pancreatic precursor cells can be identified and isolated using Notch and its ligands. This technology describes methods for identifying pancreatic precursor cells using a Notch ligand, as well as methods for isolating pancreatic precursor cells from a pancreatic cell sample, such as pancreatic islet cells or pancreatic extra-islet cells from a diabetic patient.

#### *Potential Commercial Applications:*

- Isolation and expansion of pancreatic progenitor cells for diabetes therapy
- Development of a diagnostic test to monitor beta cell function

#### *Competitive Advantages:*

- New diagnostic strategies for diabetes
- Potential use in regenerative medicine (pancreatic precursor cells recently have been shown to have the potential to develop into other cell types)

#### *Development Stage:*

- Early-stage
- In vitro data available

*Inventors:* Josephine M. Egan and Maire Doyle (NIA)

*Publication:* Kim W, *et al.* Notch signaling in pancreatic endocrine cell and diabetes. *Biochem Biophys Res Commun.* 2010 Feb 12;392(3):247-51. [PMID 20035712]

*Intellectual Property:* HHS Reference No. E-262-2003/0 —

- U.S. Provisional Application No. 60/590,281 filed 22 Jul 2004
- PCT Application No. PCT/US2005/026207 filed 22 Jul 2005, which published as WO 2006/023209 on 02 Mar 2006

• U.S. Patent No. 7,888,116 issued 15 Feb 2012

*Licensing Contact:* Tara L. Kirby, Ph.D.; 301-435-4426; [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov)

Dated: August 28, 2012.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2012-21749 Filed 9-4-12; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Healthcare Delivery and Methodologies Integrated Review Group, Health Disparities and Equity Promotion Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hotel Monaco Alexandria, 480 King Street, Alexandria, VA 22314.

*Contact Person:* Delia Olufokunbi Sam, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, 301-435-0684, [olufokunbisamd@csr.nih.gov](mailto:olufokunbisamd@csr.nih.gov).

*Name of Committee:* Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group, Biomedical Imaging Technology B Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Lee Rosen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5116, MSC 7854, Bethesda, MD 20892, (301) 435-1171. [rosenl@csr.nih.gov](mailto:rosenl@csr.nih.gov).

*Name of Committee:* Immunology Integrated Review Group, Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Renaissance Washington Dupont Circle, 1143 New Hampshire Avenue, Washington, DC 20037.

*Contact Person:* Bahiru Gametchu, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4204, MSC 7812, Bethesda, MD 20892, 301-408-9329, [gametchb@csr.nih.gov](mailto:gametchb@csr.nih.gov).

*Name of Committee:* Cell Biology Integrated Review Group, Membrane Biology and Protein Processing Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* One Washington Circle Hotel, One Washington Circle, Washington, DC 20037.

*Contact Person:* Janet M Larkin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5142, MSC 7840, Bethesda, MD 20892, 301-806-2765, [larkinja@csr.nih.gov](mailto:larkinja@csr.nih.gov).

*Name of Committee:* Biological Chemistry and Macromolecular Biophysics Integrated Review Group, Biochemistry and Biophysics of Membranes Study Section.

*Date:* October 4, 2012.

*Time:* 8 a.m. to 7 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2033 M Street NW., Washington, DC 20036.

*Contact Person:* Nuria E. Assa-Munt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4164, MSC 7806, Bethesda, MD 20892, (301) 451-1323, [assamunu@csr.nih.gov](mailto:assamunu@csr.nih.gov).

*Name of Committee:* Biological Chemistry and Macromolecular Biophysics Integrated Review Group, Macromolecular Structure and Function C Study Section.

*Date:* October 4, 2012.

*Time:* 8 a.m. to 7 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel Washington, 1515 Rhode Island Ave. NW., Washington, DC 20005.

*Contact Person:* William A. Greenberg, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4168, MSC 7806, Bethesda, MD 20892, (301) 435-1726, [greenbergwa@csr.nih.gov](mailto:greenbergwa@csr.nih.gov).

*Name of Committee:* Immunology Integrated Review Group, Transplantation, Tolerance, and Tumor Immunology Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Renaissance Washington, Dupont Circle, 1143 New Hampshire Avenue NW., Washington, DC 20037.

*Contact Person:* Jin Huang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4199, MSC 7812, Bethesda, MD 20892, 301-435-1230, [jh377p@nih.gov](mailto:jh377p@nih.gov).

*Name of Committee:* Musculoskeletal, Oral and Skin Sciences Integrated Review Group, Skeletal Biology Structure and Regeneration Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Daniel F McDonald, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4110, MSC 7814, Bethesda, MD 20892, (301) 435-1215, [mcdonald@csr.nih.gov](mailto:mcdonald@csr.nih.gov).

*Name of Committee:* Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group, Biomedical Imaging Technology A Study Section.

*Date:* October 4-5, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Behrouz Shabestari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5126, MSC 7854, Bethesda, MD 20892, (301) 435-2409, [shabestb@csr.nih.gov](mailto:shabestb@csr.nih.gov).

*Name of Committee:* Population Sciences and Epidemiology Integrated Review Group, Kidney, Nutrition, Obesity and Diabetes Study Section.

*Date:* October 4-5, 2012.